Product
Sacubitril / Valsartan
Aliases
Sacubitril / Valsartan Oral Tablet [Entresto]
5 clinical trials
8 indications
Indication
Systemic Right VentricleIndication
Congestive Heart FailureIndication
Congenital Heart DiseaseIndication
ChagasIndication
Sacubitril and ValsartanIndication
HypertensionIndication
ObesityIndication
COVID-19Clinical trial
Prospective Comparison of ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart FailureStatus: Terminated, Estimated PCD: 2023-03-01
Clinical trial
National Registry of Adult Heart Failure Patients With Complex Congenital Heart Disease: Systemic Right Ventricle and Single Ventricle Treated With Sacubitril/ValsartanStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: Randomized Trial ANSWER-HFStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Effect of Sacubitril/Valsartan on Cardiac Function Assessed by Cardiac Magnetic Resonance (CMR) in Hypertensive Patients Stratified by Body Mass Index (BMI): A Real World StudyStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019Status: Completed, Estimated PCD: 2023-06-13